Merck is a leading science and technology company, and has many projects that are involved in research to find treatments for diseases that are hard to treat. Keeping in view with this agenda, Merck has announced that the new research that has been conducted from their marketed and pipeline compounds will be presented at this year’s European Society for Medical Oncology annual meeting in Denmark. The presentations are to be focussed on hard-to-treat cancers, and will include results for Erbitux® (cetuximab) in metastatic colorectal cancer (mCRC) and squamous cell carcinoma of the head and neck (SCCHN); preliminary study results in bladder cancer and renal cell carcinoma (RCC) for avelumab, which is being developed in collaboration with Pfizer; and updates on the Phase II program for tepotinib* in non-small cell lung cancer (NSCLC).
DelveInsight Blog
Related Article
![pharma-news-for-ipsen-synox-roche-abbvie pharma-news-for-ipsen-synox-roche-abbvie](https://assets.delveinsight.com/blog/wp-content/uploads/2024/04/23170413/pharma-news-for-ipsen-synox-roche-abbvie.png)
Ipsen and Skyhawk Therapeutics Partnership; SynOx Therapeutics’ Phase III Trial; Roche’s Alecensa FDA Approval; AbbVie’s RINVOQ Phase III SELECT-GCA Trial; AskBio’s AB-1002 FDA Fast Track Designation
Ipsen Partners with Skyhawk Therapeutics for RNA-Focused Research in Rare Neurological Disorders Ipsen and Skyhawk Therapeutics have entered into an exclusive global partnership to explore and create new small molecules that can influence RNA for rare neurological conditions. Under this agreement, Ipsen has the ...
Find More![trop2-inhibitors-for-cancer-treatment trop2-inhibitors-for-cancer-treatment](https://assets.delveinsight.com/blog/wp-content/uploads/2024/03/14142759/trop2-inhibitors-for-cancer-treatment.png)
Unveiling the Potential of TROP-2 Inhibitors: A New Frontier in Cancer Treatment
Trophoblast cell surface antigen-2 (TROP-2) is a 35-kDa protein found on cell membranes, made of sugars and a protein chain, serving as a transmitter of calcium signals. It is produced by the TACSTD2 gene and shares a structural similarity with the epithelial cell adhesion molecule (EpCAM). TROP2, although ident...
Find More![Pharma News For Astellas, AnaMar, Biosyngen Pharma News For Astellas, AnaMar, Biosyngen](https://assets.delveinsight.com/blog/wp-content/uploads/2024/02/06151054/pharma-news-for-astellas-anamar-biosyngen.png)
4DMT Presents Data From Phase II PRISM Clinical Trial; Adaptimmune Announces FDA Acceptance of Biologics License Application for Afami-cel; Astellas Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA; AnaMar Announces US and EU Orphan Drug Designation for AM1476; Biosyngen Announces FDA Fast Track Designation for BST02; Acepodia Announces FDA Clearance of IND Application for ACE2016
4DMT Presents Positive Interim Data from Randomized Phase II PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD 4D Molecular Therapeutics, a prominent company in the field of genetic medicines with a focus on harnessing the full potential of geneti...
Find MoreEditor's Pick
Newsletter/Whitepaper
Recent Article
ASCO Conference 2024
![ASCO 2023 ASCO 2023](https://assets.delveinsight.com/img/events/american-society-of-clinical-oncology-conference-2024.png)
Live Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!